Literature DB >> 1978323

Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia.

A Perkins1, K Kongsuwan, J Visvader, J M Adams, S Cory.   

Abstract

In the murine myelomonocytic leukemia WEHI-3B, proviral insertions have induced expression of the Hox-2.4 homeobox gene and the gene for the myeloid growth factor interleukin 3 (IL-3). To assess their potential oncogenic role, normal bone marrow cells were infected with retroviruses bearing the genes for IL-3 or IL-3 plus Hox-2.4. Unlike the IL-3 virus, the IL-3/Hox-2.4 virus was highly leukemogenic. Infected cells expressing both genes exhibited retarded differentiation in vitro, generated myelomonocytic cell lines, and provoked a rapid, transplantable myeloid leukemia in vivo. The oncogenic action of Hox-2.4 appears to derive from its ability to impede the IL-3-driven terminal differentiation of myeloid cells. The results suggest that homeobox genes can regulate key differentiation processes such as self-renewal capacity and that their inappropriate expression can be oncogenic.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978323      PMCID: PMC54963          DOI: 10.1073/pnas.87.21.8398

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content.

Authors:  N L Warner; M A Moore; D Metcalf
Journal:  J Natl Cancer Inst       Date:  1969-10       Impact factor: 13.506

2.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

3.  Two homoeo box loci mapped in evolutionarily related mouse and human chromosomes.

Authors:  M Rabin; C P Hart; A Ferguson-Smith; W McGinnis; M Levine; F H Ruddle
Journal:  Nature       Date:  1985 Mar 14-20       Impact factor: 49.962

4.  Properties of haematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell?

Authors:  G S Hodgson; T R Bradley
Journal:  Nature       Date:  1979-10-04       Impact factor: 49.962

5.  Homeo box gene complex on mouse chromosome 11: molecular cloning, expression in embryogenesis, and homology to a human homeo box locus.

Authors:  C P Hart; A Awgulewitsch; A Fainsod; W McGinnis; F H Ruddle
Journal:  Cell       Date:  1985-11       Impact factor: 41.582

6.  Expression of genes transferred to haemopoietic stem cells by recombinant retroviruses.

Authors:  D D Bowtell; G R Johnson; A Kelso; S Cory
Journal:  Mol Biol Med       Date:  1987-08

7.  Constitutive synthesis of interleukin-3 by leukaemia cell line WEHI-3B is due to retroviral insertion near the gene.

Authors:  S Ymer; W Q Tucker; C J Sanderson; A J Hapel; H D Campbell; I G Young
Journal:  Nature       Date:  1985 Sep 19-25       Impact factor: 49.962

8.  Generation of an autocrine leukaemia using a retroviral expression vector carrying the interleukin-3 gene.

Authors:  A J Hapel; G Vande Woude; H D Campbell; I G Young; T Robins
Journal:  Lymphokine Res       Date:  1986

9.  A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL.

Authors:  M P Kamps; C Murre; X H Sun; D Baltimore
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

10.  Growth of factor-dependent hemopoietic precursor cell lines.

Authors:  T M Dexter; J Garland; D Scott; E Scolnick; D Metcalf
Journal:  J Exp Med       Date:  1980-10-01       Impact factor: 14.307

View more
  39 in total

1.  Differential and common leukemogenic potentials of multiple NUP98-Hox fusion proteins alone or with Meis1.

Authors:  Nicolas Pineault; Carolina Abramovich; Hideaki Ohta; R Keith Humphries
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

2.  Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL.

Authors:  C Lavau; S J Szilvassy; R Slany; M L Cleary
Journal:  EMBO J       Date:  1997-07-16       Impact factor: 11.598

3.  HOX11, a homeobox-containing T-cell oncogene on human chromosome 10q24.

Authors:  M A Kennedy; R Gonzalez-Sarmiento; U R Kees; F Lampert; N Dear; T Boehm; T H Rabbitts
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

4.  Coordinate regulation of HOX genes in human hematopoietic cells.

Authors:  M C Magli; P Barba; A Celetti; G De Vita; C Cillo; E Boncinelli
Journal:  Proc Natl Acad Sci U S A       Date:  1991-07-15       Impact factor: 11.205

5.  A conserved role for Hox paralog group 4 in regulation of hematopoietic progenitors.

Authors:  Michelina Iacovino; Carmen Hernandez; Zhaohui Xu; Gagan Bajwa; Melissa Prather; Michael Kyba
Journal:  Stem Cells Dev       Date:  2009-06       Impact factor: 3.272

6.  Paralogous mouse Hox genes, Hoxa9, Hoxb9, and Hoxd9, function together to control development of the mammary gland in response to pregnancy.

Authors:  F Chen; M R Capecchi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

7.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b.

Authors:  E Kroon; J Krosl; U Thorsteinsdottir; S Baban; A M Buchberg; G Sauvageau
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

Review 8.  Crossing paths: interactions between the cell death machinery and growth factor survival signals.

Authors:  Gabriela Brumatti; Marika Salmanidis; Paul G Ekert
Journal:  Cell Mol Life Sci       Date:  2010-02-16       Impact factor: 9.261

Review 9.  Hox genes in the lung.

Authors:  C Kappen
Journal:  Am J Respir Cell Mol Biol       Date:  1996-08       Impact factor: 6.914

10.  Transformation properties of the E2a-Pbx1 chimeric oncoprotein: fusion with E2a is essential, but the Pbx1 homeodomain is dispensable.

Authors:  K Monica; D P LeBrun; D A Dedera; R Brown; M L Cleary
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.